Published in Arch Dermatol on June 01, 1974
Pemphigus-like antigens and antibodies in benign and malignant neoplasms. Arch Dermatol Res (1983) 0.75
Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol (1987) 2.51
Immunofluorescence abnormalities in lichen planopilaris. Arch Dermatol (1992) 2.02
Aetiology of Kaposi's sarcoma. Lancet (1990) 1.95
Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med (1970) 1.70
Antibodies to normal human melanocytes in vitiligo. J Exp Med (1983) 1.50
Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol (2000) 1.42
Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res (1991) 1.40
Association of tissue-fixed cytoplasmic deposits of immunoglobulin in epidermal keratinocytes with lupus erythematosus. Arch Dermatol (1993) 1.38
Identification of a 160-kD molecule as a component of the basement membrane zone and as a minor bullous pemphigoid antigen. J Invest Dermatol (1990) 1.36
Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol (1970) 1.22
The effect of estrogen on the incorporation of 3H-thymidine by PHA-stimulated human peripheral blood lymphocytes. J Immunol (1974) 1.21
Pemphigus foliaceus. Subcorneal intercellular antibodies of unique specificity. Arch Dermatol (1974) 1.20
Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies. Arch Dermatol (1990) 1.19
Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol (1970) 1.18
Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol (1991) 1.15
Comparison of alopecia areata in human and nonhuman mammalian species. Pathobiology (1998) 1.14
Antibodies to hair follicles in alopecia areata. J Invest Dermatol (1994) 1.13
Sepcific removal of in vivo antibody by extracorporeal circulation over an immunoadsorbent in gel. J Clin Invest (1971) 1.13
Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"? Exp Dermatol (2006) 1.13
Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol (1995) 1.12
Thymus-specific antigens on human thymocytes and on thymic-derived lymphocytes. Transplantation (1973) 1.10
IgE in pemphigus. Arch Dermatol (1977) 1.09
Immunologic studies of normal, benign, and malignant human prostatic tissue. Cancer (1972) 1.09
Absence of intercellular antigens in the deep layers of the epidermis in pemphigus foliaceus. J Clin Invest (1978) 1.08
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol (1998) 1.05
Epidermal cytoplasmic antibodies: incidence and type in normal persons and patients with melanoma. J Invest Dermatol (1976) 1.05
Regional variation in the expression of bullous pemphigoid antigen and location of lesions in bullous pemphigoid. J Invest Dermatol (1984) 1.04
Precipitating antigens of the normal human prostate. J Reprod Fertil (1970) 1.04
Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol (2000) 1.04
Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol (1988) 1.02
Pemphigus-like antibodies in patients with skin burns. Vox Sang (1969) 1.02
Different populations of melanocytes are present in hair follicles and epidermis. Pigment Cell Res (1996) 1.01
Alopecia areata: an autoimmune disease? Exp Dermatol (1999) 1.01
Binding of antigen by immunocytes. I. Effect of ligand valence on binding affinity of MOPC 315 cells for DNP conjugates. J Exp Med (1973) 1.00
Adjuvant therapy of pemphigus. Arch Dermatol (1984) 0.99
Limitations in the diagnosis of vesiculobullous diseases. Am J Dermatopathol (1983) 0.99
Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate. Exp Med Surg (1969) 0.98
Antibodies against the cytoplasm of human epidermal cells. Arch Dermatol (1973) 0.98
Serum proteins in patients with benign and malignant diseases of the prostate. Neoplasma (1971) 0.97
Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol (1986) 0.97
Blood product immunosuppression and the acquired immunodeficiency syndrome. Ann Intern Med (1986) 0.97
Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol (1993) 0.97
Identification and solubilization of iodinated cell surface human melanoma associated antigens. Int J Cancer (1977) 0.96
Identification and purification of a Mr 75,000 cell surface human melanoma-associated antigen. Cancer Res (1982) 0.95
Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. Hybridoma (1982) 0.93
Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin. J Invest Dermatol (1991) 0.93
Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol (1992) 0.92
Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol (1979) 0.91
Alterations of alpha2-globulin and the clinical response in patients with prostatic cancer following cryotherapy. Oncology (1975) 0.91
Antibodies to melanocytes. Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis. Arch Dermatol (1981) 0.90
Tissue- and species-specific antibodies in antithymocyte globulin. Transplantation (1972) 0.90
Localization of immunoglobulins in human prostatic tissue. J Immunol (1971) 0.90
Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate. Cancer Res (1978) 0.89
Hormonal therapy and alteration of lymphocyte proliferation. J Lab Clin Med (1976) 0.89
Pemphigus, pemphigoid, and epidermal upper-cytoplasmic antigens: changes in expression in cultured human keratinocytes. Arch Dermatol Res (1981) 0.88
Substrate specificity of anti-epithelial antibodies of pemphigus vulgaris and pemphigus foliaceus sera in immunofluorescence tests on monkey and guinea pig esophagus sections. J Invest Dermatol (1987) 0.88
Immunochemical characterization of epithelial antigen(s) reactive with pemphigus-like antibodies of rabbit and human pemphigus autoantibodies. J Hyg Epidemiol Microbiol Immunol (1969) 0.87
The female prostate and prostate-specific antigen. Immunohistochemical localization, implications of this prostate marker in women and reasons for using the term "prostate" in the human female. Histol Histopathol (2000) 0.87
Heterogeneity of pemphigoid antigens. J Invest Dermatol (1983) 0.87
Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol (1985) 0.87
Condylomata acuminata: treatment by autogenous vaccine. IMJ Ill Med J (1975) 0.87
Cancer, immunological surveillance, and 2 -globulin. Lancet (1972) 0.86
Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. Br J Dermatol (1996) 0.86
Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer (1997) 0.85
Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. I. Identification of anti-tumour cell-mediated immunity and "blocking" factor. Eur J Cancer (1977) 0.85
Characterization of vitiligo antigens. Pigment Cell Res (1995) 0.85
Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol (1983) 0.85
Laryngeal and nasal involvement in pemphigus vulgaris. J Am Acad Dermatol (2001) 0.85
Detection of immunoglobulin G antibodies in melanoma sera reactive with intracellular proteins. J Invest Dermatol (1988) 0.85
Isolation and long-term culture of human hair-follicle melanocytes. J Invest Dermatol (1995) 0.84
Identification of cicatricial pemphigoid antigens. Arch Dermatol (1992) 0.84
Lipofuscin granules in normal, benign and malignant human prostatic tissue. Urol Res (1973) 0.84
Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Med (1986) 0.84
Direct immunofluorescence studies in alopecia areata and male pattern alopecia. J Invest Dermatol (1979) 0.83
Immunopathologic studies of experimental pemphigus-like autoantibodies and bullous-like lesions. J Invest Dermatol (1969) 0.83
Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens. J Immunol (1978) 0.83
Transglutaminase: co-factor in aetiology of AIDS? Lancet (1985) 0.83
Immunofluorescence studies in transient acantholytic dermatosis (Grover's disease). Am J Dermatopathol (1979) 0.83
Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol (1997) 0.83
Epiluminescence microscopy: a reevaluation of its purpose. Arch Dermatol (2001) 0.83
A tissue type transglutaminase in human seminal plasma. Am J Reprod Immunol (1997) 0.82
Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma. Eur J Cancer (1980) 0.82
Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res (1995) 0.82
Differentiation and shedding of surface macromolecules of human keratinocytes. J Invest Dermatol (1984) 0.82
Epidermal antigens. Int J Dermatol (1977) 0.82
Hair follicle structures targeted by antibodies in patients with alopecia areata. Arch Dermatol (1997) 0.82
In vivo bound immunoglobulins in the human prostate--their identification and possible significance. Z Immunitatsforsch Exp Klin Immunol (1972) 0.82
Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res (1986) 0.82
A retrospective look at studies on prostate-specific antigen. Clin Chem (1985) 0.82
Release of tumor-associated antigens by murine melanoma cells. J Immunol (1976) 0.82
Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am J Clin Oncol (1982) 0.82
Effect of substrate on indirect immunofluorescence tests for intercellular and basement membrane zone antibodies. J Am Acad Dermatol (1986) 0.82
Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol (1990) 0.82
Epidermal cytoplasmic antigens: II. Concurrent presence of antigens of different specificities in normal human skin. J Invest Dermatol (1978) 0.81
Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. J Biol Response Mod (1989) 0.81
Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer (1995) 0.81
Clearance of iodoantipyrene from methacholine blanched skin in atopics. Arch Dermatol (1969) 0.81
Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res (1991) 0.81
Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. Thromb Haemost (1988) 0.81
Freezing of the esophagus: histological changes and immunological response. Int Surg (1982) 0.81